Newlin, Richard H. Lorraine, William H.

D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of October 25, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of October 25, 2021 86 92 85 82 79 77 74 89 83 82 80 79 79 78 78 72 33 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E H X L B N R A S H E C L E M N H U N S C L A L B (12) Source: Peer data per Bloomberg market data as of October 25, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $580M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 11.0 18.3 16.3 15.4 14.5 11.6 11.1 36.2 28.0 24.9 13.0 11.5 11.3 10.0 9.2 8.8 7.7 6.7 A vi e n t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N S U M M A RY: W H Y I N V E S T I N AV I E N T ?

Microsoft PowerPoint - Avient Q4 Earnings and 2021 Outlook PRINT AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 0 R E S U L T S A N D 2 0 2 1 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 9 , 2 0 2 1 D I S C L A I M E R 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi e n t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi e n t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x S U M M A RY: W H Y I N V E S T I N AV I E N T ?

The portfolio includes color concentrates for the typical yellowish green, blue, blue-green, aqua and violet glow emissions.

Base Resin PC PC/PSU PES PEI PP ABS PEEK PA Barrel Temperatures* °F (°C) Rear Zone 530–560 (277–293) 550–575 (288–302) 660–700 (349–371) 675–725 (357–385) 390–420 (199–216) 425–460 (219–238) 680–730 (360–388) 430–500 (221–260) Center Zone 515–560 (269–288) 540–565 (282–296) 650–690 (343–366) 655–710 (352–377) 380–405 (193–207) 415–450 (213–232) 670–710 (354–377) 420–490 (216–254) Front Zone 510–525 (266–274) 530–555 (277–291) 640–680 (338–360) 655–700 (346–371) 370–395 (188–202) 405–440 (207–227) 650–690 (343–366) 410–480 (210–249) Nozzle 520–535 (271–280) 540–565 (282–296) 650–690 (343–366) 665–710 (352–377) 380–400 (193–204) 415–450 (213–232) 660–700 (349–371) 420–490 (216–254) Melt Temperature 525–560 (274–293) 530–580 (277–304) 650–700 (343–371) 660–730 (349–388) 375–395 (191–202) 410–460 (210–238) 650–730 (343–388) 420–500 (216–260) Mold Temperature 175–250 (80–121) 160–220 (71–104) 280–350 (138–177) 275–350 (135–177) 100–135 (38–57) 150–180 (66–82) 300–425 (149–219) 160–230 (71–110) Pack & Hold Pressure 50%–75% of Injection Pressure Injection Velocity in/s 0.5–2.0 Back Pressure psi 50 Screw Speed rpm 40–70 40–70 40–70 40–70 40–70 40–70 40–70 40–70** Drying Parameters °F (°C) 6 hrs @ 250 (121) 4 hrs @ 250 (121) 4 hrs @ 275 (135) 4 hrs @ 250 (121) 3 hrs @ 300 (150) 2 hrs @ 200 (93) 3 hrs @ 275 (135) 4 hrs @ 180 (82) Cushion in 0.125–0.250 Screw Compression Ratio 2.0:1–2.5:1 2.0:1–2.5:1 2.5:1–3.5:1 2.5:1–3.5:1 2.5:1–3.5:1 2.5:1–3.5:1 2.5:1–3.5:1 2.5:1–3.5:1 Nozzle Type General Purpose General Purpose General Purpose General Purpose General Purpose General Purpose General Purpose Reverse Taper Clamp Pressure 5–6 Tons/in2 * A reverse temperature profile is important to obtain optimum conductive properties. Only naturally balanced runner systems (“H” pattern) are recommended

Nymax™ / Bergamid™ Polyamide Formulations Bergamid™ polymer formulations and GLS™ TPEs replace metal and provide comfort and usability for Swiss soldiers pocket knife Bergamid™ Polymer Formulations and GLS™ TPEs provide comfort and usability in iconic pocket knife handle

BENEFITS OF VERSAFLEX PF FOR SURFACE PROTECTIVE FILMS: • Customizable tack • Single-step manufacturing process (co- extrusion) • Low volatile organic compound (VOC) emissions during manufacturing • Eliminates secondary coating and drying operations • Eliminates hazardous liquid chemicals compared to solvent systems • Reduces converting costs versus coating • Reduces energy consumption MARKETS AND APPLICATIONS Versaflex PF formulations, customizable based on desired level of tack, are co-extruded with protective films to provide just the right amount of protection during the fabrication, assembly, shipment, storage and installation of finished goods in many industries and end-use applications including: • Optical films and display panels for consumer electronics • Home appliances • Construction and building materials • Furniture and cabinetry • Automotive and other transportation 100/0 90/10 80/20 70/30 60/40 40/60 30/70 20/80 10/90 0/100 0.9 1.1 2.0 2.4 2.8 3.7 3.8 4.9 0 1 2 3 4 5 6 7 8 6.5 1.6 Versaflex PF MD6727 Versaflex PF MD6748 Versaflex PF MD6700 Versaflex PF MD6666 Versaflex PF 9512 Versaflex PF MD6649 Versaflex PF MD6741 0 2 4 6 8 10 12 % of MD6741/MD6700 Degree of tack can be customized for substrate surfaces. TAILORING TACK BY BLENDING VERSAFLEX PF Film Thickness: 39 micron LDPE/13 micron Versaflex PF F = Final tack after 7 days @ 25° C i = Initial tack after 20 mins @ 25° C Pe el S tr en gt h on S te el , N /2 5m m Pe el S tr en gt h on S te el , N /2 5m m PEEL STRENGTH ON STAINLESS STEEL Film Thickness: 51 micron LDPE/25 micron Versaflex PF F F F F F F F i i i i i i i www.avient.com Copyright © 2020, Avient Corporation.

W H O W E A R E – V I S I O N , S T R AT E G Y, C U LT U R E 3 Avient Corporation (NYSE: AVNT) provides specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of November 8, 2021 86 93 85 83 79 77 75 89 85 83 81 79 79 78 77 74 25 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E B N R H X L A S H E C L E M N H U N S C L A L B (10) Source: Peer data per Bloomberg market data as of November 8, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below many of our specialty formulator peers. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 33 Avient reflects 2021 estimated EBITDA of $580M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 11.4 20.2 16.7 16.5 14.7 12.0 10.8 40.7 29.9 26.2 13.2 12.4 11.0 10.9 9.1 9.0 7.5 6.5 A vi e n t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N S U M M A RY: W H Y I N V E S T I N AV I E N T ?

H Y P O D E R M I C N E E D L E M A N U FAC T U R E R N E E D L E H U B , C O V E R A N D S H I E L D • Compliance to ISO 6009 color coding for single use hypodermic needle • Biocompatibility of all component materials • Good mechanical and visual properties after sterilization (e.g.

AU TO M O T I V E M I R R O R & C A M E R A M A N U FA C T U R E R C A B L E G R O M M E T • Electrically conductive